Amarin Corporation plc (AMRN - Free Report) was a big mover last session, as the company saw its shares rise almost 7% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This continues the recent uptrend for the company since May 12, as the stock is now up almost 37%.
In the last 30 days, the company has seen one downward estimate revision and the Zacks Consensus Estimate also moved lower, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.
Amarin currently carries a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
A better-ranked Bio-medical/Gene stock is ANI Pharmaceuticals, Inc. (ANIP - Free Report) , which sports a Zacks Rank #1 (Strong Buy).
Is AMRN going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Amarin Corporation plc (AMRN - Free Report) was a big mover last session, as the company saw its shares rise almost 7% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This continues the recent uptrend for the company since May 12, as the stock is now up almost 37%.
In the last 30 days, the company has seen one downward estimate revision and the Zacks Consensus Estimate also moved lower, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.
Amarin currently carries a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
A better-ranked Bio-medical/Gene stock is ANI Pharmaceuticals, Inc. (ANIP - Free Report) , which sports a Zacks Rank #1 (Strong Buy).
Is AMRN going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on AMRN - FREE
Get the latest research report on ANIP - FREE